Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theravance Bio Ord (NQ: TBPH )

11.15 -0.02 (-0.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 435,570
Open 11.13
Bid (Size) 10.88 (1)
Ask (Size) 11.40 (1)
Prev. Close 11.17
Today's Range 10.99 - 11.19
52wk Range 7.530 - 12.03
Shares Outstanding 57,797,468
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'... 
Via Benzinga
Earnings Scheduled For May 8, 2023
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million. 
Via Benzinga

Performance

YTD
+1.64%
+1.64%
1 Month
-1.59%
-1.59%
3 Month
+9.96%
+9.96%
6 Month
+4.21%
+4.21%
1 Year
+24.30%
+24.30%

More News

Read More
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
Via Benzinga
Earnings Preview: Theravance Biopharma
Via Benzinga
Theravance Biopharma Finally Shelves Failed JAK Inhibitor Program, Lays Off Staff
Via Benzinga
Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review
From Irenic Capital Management, LP
Via Business Wire
Target To Rally 29%? Plus This Analyst Predicts $245 For IQVIA Holdings
Via Benzinga
A Preview Of Theravance Biopharma's Earnings
Via Benzinga
Here's Why Theravance Biopharma Shares Are Moving
Via Benzinga
Earnings Scheduled For February 27, 2023
Via Benzinga
Earnings Scheduled For November 7, 2022
Via Benzinga
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
Via Benzinga
Looking Into Theravance Biopharma's Return On Capital Employed
Via Benzinga
Theravance Biopharma's Earnings: A Preview
Via Benzinga
Why Is Conagra Brands Dropping By More Than 8%? 43 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Why Is Ericsson Down By 9%? 22 Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Theravance Biopharma's Earnings Outlook
Via Benzinga
Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.